See more : Interma Trade S.A. (ITM.WA) Income Statement Analysis – Financial Results
Complete financial analysis of AVITA Medical, Inc. (RCEL) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of AVITA Medical, Inc., a leading company in the Medical – Devices industry within the Healthcare sector.
You may be interested
- Saint-Care Holding Corporation (2374.T) Income Statement Analysis – Financial Results
- Morella Corporation Limited (1MC.AX) Income Statement Analysis – Financial Results
- Maoyan Entertainment (1896.HK) Income Statement Analysis – Financial Results
- Latin Metals Inc. (LMSQF) Income Statement Analysis – Financial Results
- Asia Broadband, Inc. (AABB) Income Statement Analysis – Financial Results
AVITA Medical, Inc. (RCEL)
About AVITA Medical, Inc.
AVITA Medical Inc. operates as a commercial-stage regenerative tissue company in the United States, Australia, and the United Kingdom. It offers regenerative products to address unmet medical needs in burn injuries, trauma injuries, chronic wounds, and dermatological and aesthetics indications, including vitiligo. The company's patented and proprietary platform technology provides treatment solutions derived from the regenerative properties of a patient's own skin. Its lead product is RECELL System, a device that enables healthcare professionals to produce a suspension of Spray-On Skin cells using a small sample of the patient's own skin for use in the treatment of acute thermal burns in patients eighteen years and older. The company has a research collaboration with the University of Colorado School of Medicine to establish pre-clinical proof-of-concept for a spray-on treatment of genetically corrected cells; and a research collaboration with Houston Methodist Research Institute to explore molecular reversal of cellular aging through a novel cell suspension delivery system. The company was formerly known as AVITA Therapeutics, Inc. and changed its name to AVITA Medical Inc. in December 2020. AVITA Medical Inc. was incorporated in 2000 and is based in Valencia, California.
| Metric | 2022 | 2020 | 2019 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2003 | 2002 | 2001 | 2000 | 1999 | 1998 | 1997 | 1996 | 1995 | 1994 | 1993 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 50.56M | 14.26M | 20.67M | 1.26M | 1.18M | 1.00M | 985.65K | 2.68M | 2.81M | 3.35M | 3.34M | 2.30M | 2.37M | 1.20M | 790.99K | 883.39K | 389.08K | 194.32K | 0.00 | 0.00 | 0.00 | 582.97K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cost of Revenue | 8.87M | 2.97M | 4.31M | 737.70K | 505.64K | 401.57K | 289.20K | 670.89K | 676.50K | 952.85K | 972.78K | 669.45K | 824.23K | 492.31K | 1.13M | 1.06M | 940.26K | 98.98K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | 41.69M | 11.29M | 16.36M | 517.47K | 675.00K | 600.44K | 696.45K | 2.01M | 2.14M | 2.40M | 2.36M | 1.63M | 1.54M | 711.35K | -337.70K | -176.85K | -551.18K | 95.34K | 0.00 | 0.00 | 0.00 | 582.97K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit Ratio | 82.45% | 79.16% | 79.16% | 41.23% | 57.17% | 59.92% | 70.66% | 75.00% | 75.97% | 71.58% | 70.84% | 70.85% | 65.18% | 59.10% | -42.69% | -20.02% | -141.66% | 49.06% | 0.00% | 0.00% | 0.00% | 100.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Research & Development | 20.35M | 8.46M | 13.28M | 8.45M | 6.27M | 3.46M | 3.77M | 2.15M | 2.60M | 969.11K | 255.54K | 164.79K | 181.85K | 163.83K | 620.67K | 1.33M | 425.97K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| General & Administrative | 34.27M | 34.62M | 46.77M | 12.70M | 0.00 | 6.51M | 2.45M | 4.27M | 5.45M | 5.34M | 5.42M | 3.40M | 3.87M | 3.98M | 5.36M | 5.64M | 2.21M | 725.90K | 480.40K | 569.49K | 235.70K | 371.78K | 97.16K | 138.81K | 126.55K | 278.48K | 207.93K |
| Selling & Marketing | 32.19M | 14.81M | 22.76M | 6.59M | 5.20M | 3.46M | 3.21M | 2.63M | 3.39M | 2.93M | 2.15M | 1.15M | 1.37M | 1.39M | 1.92M | 1.90M | 838.56K | 122.35K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 66.46M | 49.43M | 70.61M | 21.21M | 13.90M | 10.93M | 5.68M | 7.09M | 8.92M | 8.44M | 7.57M | 4.55M | 5.24M | 5.37M | 7.28M | 7.54M | 3.05M | 848.25K | 480.40K | 569.49K | 235.70K | 371.78K | 97.16K | 138.81K | 126.55K | 278.48K | 207.93K |
| Other Expenses | 0.00 | 686.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 852.27K | 886.45K | 41.73K | 5.88K | 4.27M | 85.29K | 240.35K | -1.28M | -24.61K | -2.08M | 28.27K | -956.00K | -1.56M | 1.52M | 910.39K | 40.34K | 16.93K |
| Operating Expenses | 80.78M | 53.97M | 77.21M | 19.15M | 13.35M | 11.95M | 9.26M | 8.83M | 10.77M | 10.66M | 7.89M | 5.23M | 5.91M | 5.75M | 8.75M | 9.62M | 4.87M | 169.38K | 670.01K | 76.87K | 235.70K | 371.78K | 97.16K | 138.81K | 126.55K | 278.48K | 207.93K |
| Cost & Expenses | 89.65M | 56.94M | 81.51M | 19.88M | 13.85M | 12.36M | 9.55M | 9.50M | 11.45M | 11.61M | 8.86M | 5.90M | 6.74M | 6.25M | 9.88M | 10.68M | 5.81M | 268.36K | 670.01K | 76.87K | 235.70K | 371.78K | 97.16K | 138.81K | 126.55K | 278.48K | 207.93K |
| Interest Income | 23.50K | 0.00 | 47.82K | 28.37K | 110.96K | 110.34K | 45.42K | 160.33K | 412.26K | 497.99K | 124.99K | 124.70K | 270.11K | 668.21K | 543.41K | 520.50K | 201.65K | 145.15K | 126.13K | 195.94K | 6.81K | 609.80 | 4.20K | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Expense | 0.00 | 33.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 12.90K | 37.65K | 78.50K | 53.20K | 8.55M | 4.86K | 9.95K | 2.26K | 3.57 | 4.97M | 576.36K | 2.07M | 2.19M | 258.33K | 1.16M | 775.70 | -191.00K |
| Depreciation & Amortization | 1.46M | 465.00K | 0.00 | 105.45K | 139.70K | 83.72K | 62.62K | 63.71K | 121.92K | 569.23K | 650.88K | 517.57K | 491.49K | 221.96K | 852.62K | 745.94K | 702.81K | 111.83K | 189.60K | 76.87K | 595.35K | -923.38K | -2.19M | 578.99K | -1.16M | -1.96M | 49.44K |
| EBITDA | -39.57M | -41.53M | -61.17M | -18.55M | -12.53M | -11.27M | -8.68M | -6.76M | -8.51M | -5.62M | -3.89M | -2.08M | -3.57M | -4.15M | -3.69M | -8.45M | -4.27M | -1.39M | -390.45K | 575.84K | 359.65K | 582.97K | -2.29M | 440.17K | -1.29M | -2.23M | -158.49K |
| EBITDA Ratio | -78.26% | -291.16% | -295.97% | -1,478.04% | -1,061.34% | -1,124.79% | -880.69% | -251.79% | -302.36% | -167.75% | -116.76% | -90.46% | -150.78% | -344.42% | -466.58% | -956.13% | -1,097.89% | -717.25% | 0.00% | 0.00% | 0.00% | 100.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Operating Income | -40.40M | -42.68M | -61.84M | -18.70M | -12.67M | -11.35M | -8.74M | -6.82M | -8.63M | -6.19M | -4.38M | -2.59M | -4.06M | -4.37M | -4.54M | -9.19M | -4.97M | -1.62M | -1.29M | 498.37K | -235.70K | 1.51M | -97.16K | -138.81K | -126.55K | -278.48K | -207.93K |
| Operating Income Ratio | -79.91% | -299.23% | -299.23% | -1,489.88% | -1,073.17% | -1,133.14% | -887.04% | -254.16% | -306.69% | -184.73% | -131.31% | -113.00% | -171.55% | -362.86% | -574.37% | -1,040.57% | -1,278.53% | -832.34% | 0.00% | 0.00% | 0.00% | 258.39% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Total Other Income/Expenses | 1.29M | 686.00K | 946.20K | 43.24K | 110.96K | 110.34K | 222.97K | 160.33K | 412.26K | -1.57M | 3.23M | -1.82M | 41.73K | -7.58M | -4.55M | 85.29K | 240.35K | -1.58M | -735.53K | -1.16M | -567.08K | -956.00K | -1.56M | 1.52M | 911.13K | 99.29K | 158.49K |
| Income Before Tax | -39.12M | -42.03M | -60.90M | -18.66M | -12.56M | -11.24M | -8.52M | -6.66M | -8.22M | -7.76M | -2.18M | -5.34M | -4.14M | -12.00M | -13.09M | -9.20M | -4.98M | -1.51M | -1.29M | -1.63M | -812.06K | -563.08K | -2.29M | 184.42K | -1.29M | -2.18M | -16.93K |
| Income Before Tax Ratio | -77.36% | -294.65% | -294.65% | -1,486.44% | -1,063.77% | -1,122.13% | -864.42% | -248.18% | -292.04% | -231.47% | -65.24% | -232.33% | -174.86% | -997.23% | -1,655.44% | -1,041.12% | -1,281.08% | -775.96% | 0.00% | 0.00% | 0.00% | -96.59% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | 52.88K | 4.00K | 5.80K | 1.45M | 1.05M | 971.88K | 653.67K | 1.51M | 128.05K | 87.76K | -90.09K | -330.41K | 78.50K | -342.23K | -316.55K | -311.92K | -7.13M | -2.69M | -2.53M | -2.94M | 576.36K | -923.38K | 2.19M | -581.57K | 1.16M | -238.92K | 208.61K |
| Net Income | -39.17M | -42.03M | -60.90M | -17.21M | -11.51M | -10.27M | -7.87M | -5.15M | -8.09M | -7.59M | -2.09M | -5.01M | -4.14M | -11.66M | -12.78M | -8.89M | -4.98M | -1.54M | -1.12M | -1.54M | -812.06K | -562.85K | -2.29M | 184.42K | -1.29M | -1.94M | -225.54K |
| Net Income Ratio | -77.47% | -294.68% | -294.68% | -1,370.83% | -974.99% | -1,025.14% | -798.10% | -191.84% | -287.49% | -226.42% | -62.54% | -217.95% | -174.86% | -968.80% | -1,615.42% | -1,005.81% | -1,281.08% | -794.76% | 0.00% | 0.00% | 0.00% | -96.55% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| EPS | -1.57 | -2.07 | -3.00 | -1.84 | -1.72 | -2.06 | -2.23 | -1.58 | -2.69 | -3.19 | -1.53 | -3.93 | -3.75 | -16.51 | -3.24 | -3.43 | -3.14 | -1.92 | -0.56 | -0.80 | -1.32 | -2.25 | -48.58 | -0.74 | -27.28 | -42.11 | -5.06 |
| EPS Diluted | -1.57 | -2.07 | -3.00 | -1.85 | -1.72 | -2.06 | -2.23 | -1.58 | -2.69 | -3.19 | -1.53 | -3.93 | -3.75 | -16.51 | -3.24 | -3.43 | -3.14 | -1.92 | -0.56 | -0.80 | -1.32 | -2.25 | -48.58 | -0.74 | -27.28 | -42.11 | -5.06 |
| Weighted Avg Shares Out | 25.00M | 20.29M | 20.29M | 9.30M | 6.69M | 4.99M | 3.53M | 3.25M | 3.01M | 2.38M | 1.36M | 1.27M | 1.10M | 706.45K | 3.94M | 2.59M | 1.59M | 806.03K | 2.00M | 1.93M | 614.53K | 249.70K | 47.13K | 47.13K | 47.13K | 46.02K | 44.55K |
| Weighted Avg Shares Out (Dil) | 25.00M | 20.29M | 20.29M | 9.33M | 6.70M | 4.99M | 3.53M | 3.25M | 3.01M | 2.38M | 1.36M | 1.27M | 1.10M | 706.45K | 3.94M | 2.59M | 1.59M | 806.03K | 2.00M | 1.93M | 614.53K | 249.70K | 47.13K | 47.13K | 47.13K | 46.02K | 44.55K |
AVITA Medical, Inc. (RCEL) Q2 2024 Earnings Call Transcript
AVITA Medical, Inc. (NASDAQ:RCEL ) Q2 2024 Earnings Conference Call August 8, 2024 8:30 AM ET Company Participants Jessica Ekeberg - Director, Investor Relations Jim Corbett - Chief Executive Officer David O'Toole - Chief Financial Officer Conference Call Participants Ryan...
AVITA Medical to Host Investor Webinar Briefing
VALENCIA, Calif., Aug. 08, 2024 (GLOBE NEWSWIRE) -- AVITA Medical, Inc. (NASDAQ: RCEL, ASX: AVH), a commercial-stage regenerative medicine company focused on first-in-class devices for wound care management and skin restoration, invites shareholders and prospective investors to attend its investor...
AVITA Medical Reports Second Quarter Financial Results
AVITA Medical today reported second-quarter commercial revenue of $15.1 million, reflecting growth of over 29% over the same period in the prior year.
AVITA Medical to Announce Second Quarter 2024 Financial Results
VALENCIA, Calif., July 11, 2024 (GLOBE NEWSWIRE) -- AVITA Medical, Inc. (NASDAQ: RCEL, ASX: AVH), a commercial-stage regenerative medicine company focused on first-in-class devices for wound care management and skin restoration, today announced that it will report its second quarter...
AVITA Medical Appoints Nicole Kelsey as Chief Legal and Compliance Officer, and Corporate Secretary
VALENCIA, Calif., July 01, 2024 (GLOBE NEWSWIRE) -- AVITA Medical, Inc. (NASDAQ: RCEL, ASX: AVH), a commercial-stage regenerative medicine company focused on first-in-class devices for wound care management and skin restoration, today announced the appointment of Nicole Linda Kelsey as...
AVITA Medical Achieves Milestone with First Case Using RECELL GO
VALENCIA, Calif., June 05, 2024 (GLOBE NEWSWIRE) -- AVITA Medical, Inc. (NASDAQ: RCEL, ASX: AVH), a commercial-stage regenerative medicine company focused on first-in-class devices for wound care management and skin restoration, today announced that the Joseph M.
AVITA Medical Announces FDA Approval of RECELL GO
VALENCIA, Calif., May 30, 2024 (GLOBE NEWSWIRE) -- AVITA Medical, Inc. (NASDAQ: RCEL, ASX: AVH), a commercial-stage regenerative medicine company focused on first-in-class devices for wound care management and skin restoration, today announced that the U.S. Food and Drug Administration...
AVITA Medical to Host Investor Webinar Briefing
VALENCIA, Calif., May 16, 2024 (GLOBE NEWSWIRE) -- AVITA Medical, Inc. (NASDAQ: RCEL, ASX: AVH), a commercial-stage regenerative medicine company focused on first-in-class devices for wound care management and skin restoration, invites shareholders and prospective investors to attend its investor...
AVITA Medical Reports First Quarter Financial Results
VALENCIA, Calif., May 13, 2024 (GLOBE NEWSWIRE) -- AVITA Medical, Inc. (NASDAQ: RCEL, ASX: AVH), a commercial-stage regenerative medicine company focused on first-in-class devices for wound care management and skin restoration, today reported financial results for the first quarter ended...
AVITA Medical to Announce First Quarter 2024 Financial Results
AVITA Medical will report first quarter 2024 financial results after the close on May 13, 2024, and host a webcast that day at 1:30 p.m. Pacific Time.
Source: https://incomestatements.info
Category: Stock Reports